However, other studies that used polyphenols such as EGCG and resveratrol for the treatment of MASLD showed a decrease in the levels of PPARγ in treated groups, while there was an increase in the levels of PPARα when a lower concentration of polyphenols was used in vitro (10 μM). Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.